Different human vaccine adjuvants promote distinct antigen-independent immunological signatures tailored to different pathogens.

ABSTRACT: The majority of vaccine candidates in clinical development are highly purified proteins and peptides relying on adjuvants to enhance and/or direct immune responses. Despite the acknowledged need for novel adjuvants, there are still very few adjuvants in licensed human vaccines. A vast number of adjuvants have been tested pre-clinically using different experimental conditions, rendering it impossible to directly compare their activity. We performed a head-to-head comparison of five different adjuvants Alum, MF59®, GLA-SE, IC31® and CAF01 in mice and combined these with antigens from M. tuberculosis, influenza, and chlamydia to test immune-profiles and efficacy in infection models using standardized protocols. Regardless of antigen, each adjuvant had a unique immunological signature suggesti

SUBMITTER: Knudsen NP 

PROVIDER: S-EPMC4726129 | biostudies-literature | 2016 Jan

REPOSITORIES: biostudies-literature